CHEMOTHERAPY STUDY WITH PREMENOPAUSIC ENDOCRINE RESPONSE (PERCHE), A PHASE III TRIAL EVALUATING THE ROLE OF CHEMOTHERAPY AS ADJUVANT THERAPY FOR PREMENOPAUSIC WOMEN WITH BREAST CANCER WITH ENDOCRINE RESPONSE WHO RECEIVE ENDOCRINE THERAPY.

INTERNATIONAL BREAST CANCER STUDY GROUP - IBCSG,0 个研究点目标入组 0 人开始时间: 2004年1月26日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•Histologically confirmed breast cancer confined to the breast and axillary nodes
•Must have undergone 1 of the following procedures for primary breast cancer within the past 12 weeks and have no known clinical residual locoregional disease:
•Breast-conserving surgery (e.g., lumpectomy, quadrantectomy, or partial mastectomy with margins clear* of invasive cancer and ductal carcinoma in situ) followed by radiotherapy NOTE: *If all other margins are clear, a positive posterior (deep) margin is permitted, provided the excision was performed down to the pectoral fascia and all tumor has been removed OR a positive anterior (superficial; abutting skin) margin is allowed provided all tumor was removed
•Patients with microscopically positive axillary sentinel nodes allowed provided they were evaluated on a clinical trial evaluating microscopically positive lymph nodes
•Total mastectomy with or without adjuvant radiotherapy
•Inflammatory breast cancer
•Supraclavicular node involvement
•Enlarged internal mammary nodes (unless pathologically negative)
•Histologically diagnosed synchronous bilateral invasive breast cancer within the past 2 months allowed if the bilateral disease meets all other eligibility criteria
•Patient must be Premenopausal, Female
•Fertile patients must use effective nonhormonal contraception

•No distant metastatic disease
•No locally advanced, inoperable breast cancer, including any of the following characteristics:
•No prior ipsilateral or contralateral invasive breast cancer
•No prior deep venous thrombosis and/or embolism unless patient is medically suitable
•No systemic cardiovascular disease that would preclude prolonged follow-up
•No systemic pulmonary disease that would preclude prolonged follow-up
•Not pregnant or nursing
•No other prior or concurrent invasive malignancy except adequately treated basal cell or squamous cell skin cancer, nonbreast carcinoma in situ without invasion, contralateral or ipsilateral carcinoma in situ of the breast
•No prior or concurrent nonbreast invasive malignancy within the past 5 years that is nonrecurrent

发起方

INTERNATIONAL BREAST CANCER STUDY GROUP - IBCSG,